Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expressions in Compound-treated vs. non-treated fibroblast of Leigh syndrome by DNA microarray analysis

ABSTRACT: Gene expressions in Compound-treated vs. non-treated fibroblast of Leigh syndrome by DNA microarray analysis

PROVIDER: PRJNA494635 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expressions in Compound-treated vs. non-treated fibroblast of Leigh syndrome by DNA microarray analysis

Project description:To overview compound-responsive genes in fibroblast, we performed microarray analysis of ~63,000 genes in compound-treated fibroblast of LSND3

2018-10-05 | GSE120817 | GEO

RNA-seq of a Leigh Syndrome patient blood being treated with Omaveloxolone.

Project description:A male patient diagnosed with Leigh Syndrome due to a compound heterizygous mutation in SURF1 (SURF1 c.312_321del10insAT (p.Leu105*); SURF1 c.574C>T (p.Arg192Trp)) was prescribed Omaveloxolone under physican supervision. Pre-treatment patient blood showed deficiency in pathways associated with oxidative phosphorylion and cellular energetics. Omaveloxolone normalized this phenotype via enrichment of these pathways.

2026-08-01 | GSE318208 | GEO

RNA-seq of a Leigh Syndrome patient blood being treated with Omaveloxolone

Project description:A patient diagnosed with Leigh Syndrome due to a compound heterizygous mutation in SURF1 (SURF1 c.312_321delinsAT (p.L105X); c.-13_11del24) was prescribed Omaveloxolone under physican supervision. Pre-treatment patient blood showed deficiency in pathways associated with oxidative phosphorylion and cellular energetics. Omaveloxolone normalized this phenotype via enrichment of these pathways. Enrichment of these pathways could be due to up-regulation of the master transcription factor PPARGC1A.

2026-08-01 | GSE306316 | GEO

RNA-seq of patient-derived glutamatergic neurons carrying Leigh Syndrome causing compound heterozygous mutations in the SURF1 gene treated with Omaveloxolone.

Project description:RNA-seq of patient-derived glutamatergic neurons carrying Leigh Syndrome causing compound heterozygous mutations in the SURF1 gene treated with Omaveloxolone.

| PRJNA1309595 | ENA

Transcriptome analysis of compound-treated cells

Project description:Transcriptome analysis of compound-treated cells

| PRJEB83388 | ENA

RNA-seq of a Leigh Syndrome patient blood being treated with Omaveloxolone

Project description:RNA-seq of a Leigh Syndrome patient blood being treated with Omaveloxolone

| PRJNA1310465 | ENA

RNA-seq of a Leigh Syndrome patient blood being treated with Omaveloxolone.

Project description:RNA-seq of a Leigh Syndrome patient blood being treated with Omaveloxolone.

| PRJNA1416919 | ENA

RNA-seq of patient-derived glutamatergic neurons carrying Leigh Syndrome causing compound heterozygous mutations in the SURF1 gene treated with Omaveloxolone.

Project description:Leigh Syndrome (LS) is a rare, progressive mitochondrial encephalopathy that manifests in infancy or early childhood and is characterized by neurodevelopmental regression, brainstem and basal ganglia lesions, and premature mortality. At the molecular level, LS is driven by mutations that impair oxidative phosphorylation (OXPHOS), disrupting energy production in metabolically active tissues such as the brain, heart, and muscle. Among these, mutations in SURF1—a nuclear gene essential for cytochrome c oxidase (COX, Complex IV) assembly—are among the most common causes of nuclear-encoded LS. Omaveloxolone, an FDA-approved Nrf2 activator for Friedreich’s Ataxia, has recently gained attention for its neuroprotective properties across a range of preclinical models. Treatment of patient neurons with omaveloxolone promoted neurite outgrowth, and activated PINK1/PRKN-mediated mitophagy. Functionally, omaveloxolone reduced neuronal hyperexcitability and apoptosis, and normalized aberrant synaptic pathway activity via deactivation of the SNARE complex.

2026-08-01 | GSE306153 | GEO

Regulation of basal and TNFa-induced fibroblast gene expressions by peptidylarginine deiminase 2

Project description:Regulation of basal and TNFa-induced fibroblast gene expressions by peptidylarginine deiminase 2

| PRJNA1327417 | ENA

Compound PIP-RBPJ-1 treated human neural stem cells

Project description:Compound PIP-RBPJ-1 treated human neural stem cells

| PRJNA432342 | ENA